A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
Abstract Encorafenib is a novel kinase inhibitor of BRAF V600E as well as wild‐type BRAF and CRAF and has received approval, in combination with binimetinib, to treat BRAF V600E or V600K mutation‐positive unresectable or metastatic melanoma or in combination with cetuximab to treat BRAF V600E mutati...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2023-10-01
|
| Edice: | Pharmacology Research & Perspectives |
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/prp2.1140 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|